Ranibizumab Therapy for Non-arteritic Ischemic Optic Neuropathy

Phase 1 Completed 2 enrolled University of Colorado, Denver Genentech, Inc. · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to explore the safety and efficacy of ranibizumab to treat non-arteritic ischemic optic neuropathy based on clinical and anatomical findings.

Timeline

Start: 2007-11
Primary completion: 2009-04
Completion: 2009-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ranibizumab	Monoclonal antibody	0.5 mg	Intravitreal

Ranibizumab Therapy for Non-arteritic Ischemic Optic Neuropathy

Summary

Timeline

Drugs

Indications